Owlstone Medical said today that it inked a strategic collaborative deal with Johnson & Johnson‘s (NYSE:JNJ) Actelion to discover and validate a breath-based test intended for the early diagnosis of pulmonary hypertension and its subtypes.
Cambridge, UK-based Owlstone Medical said that the collaborative development program will be funded solely by Actelion, and that it will initially involve collecting breath exhaled volatile organic compounds from over 1,000 patients using Owlstone’s ReCIVA sampling device.
Samples collected will be analyzed by Owlstone Medical to identify those associated with pulmonary hypertension in an effort to develop a biomarker signature to facilitate earlier detection of the disease.
“Owlstone Medical was founded with the objective of improving the early diagnosis of disease in order to save lives through the application of Breath Biopsy. This strategic collaboration with Actelion, which is focused on improving the lives of those suffering from PH and PAH, represents a tremendous opportunity to do just that. This is particularly true in underdiagnosed areas such as PH, where early diagnosis is difficult and so screening has to be simple, reliable, and cost effective. We believe Breath Biopsy will deliver a program from discovery through to the launch of a test to the market, and this novel approach will make a real difference for the healthcare of patients suffering from PH,” Owlstone Medical co-founder & CEO Billy Boyle said in a press release.
Last October, Owlstone Medical said that it raised $50 million (UK £38 million) in a round of financing, with funds slated to help support the targeted launch of its breath biopsy kits and continued development of its technology platforms.